Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by MorphoSys AG MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market July 12, 2024 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders June 20, 2024 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports First Quarter 2024 Financial Results April 29, 2024 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis April 11, 2024 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study December 10, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction November 20, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results November 15, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results August 09, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports First Quarter 2023 Financial Results May 03, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update March 15, 2023 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results November 16, 2022 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters August 31, 2022 From MorphoSys AG Via Business Wire MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results August 03, 2022 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 July 28, 2022 From MorphoSys AG Via AccessWire Tickers MOR MPSYF MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 From MorphoSys AG Via AccessWire Tickers MOR MPSYF MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 July 26, 2022 From MorphoSys AG Via AccessWire Tickers MOR MPSYF MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 June 14, 2022 From MorphoSys AG Via Business Wire Tickers MOR MorphoSys AG Reports Outcome of Annual General Meeting 2022 May 18, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys AG Reports First Quarter 2022 Financial Results May 04, 2022 From MorphoSys AG Via Business Wire Tickers MOR Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022 April 28, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL March 22, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 16, 2022 From MorphoSys AG Via Business Wire Tickers MOR National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas March 15, 2022 From MorphoSys AG Via AccessWire Tickers MOR Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022 March 10, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021 March 10, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report January 24, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance January 18, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference January 10, 2022 From MorphoSys AG Via AccessWire Tickers MOR MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis December 12, 2021 From MorphoSys AG Via AccessWire Tickers MOR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.